Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus

The Cochrane Database of Systematic Reviews
B RichterChristian Lerch

Abstract

In type 2 diabetes mellitus there is a progressive loss of beta-cell function. One new approach yielding promising results is the use of the orally active dipeptidyl peptidase-4 (DPP-4) inhibitors like sitagliptin and vildagliptin. To assess the effects of dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Studies were obtained from computerised searches of MEDLINE, EMBASE and The Cochrane Library. Studies were included if they were randomised controlled trials in adult people with type 2 diabetes mellitus and had a trial duration of at least 12 weeks. Two authors independently assessed risk of bias and extracted data. Pooling of studies was performed by means of fixed-effect meta-analysis. Twenty-five studies of good quality were identified, 11 trials evaluated sitagliptin and 14 trials vildagliptin treatment. Altogether, 6743 patients were randomised in sitagliptin and 6121 patients in vildagliptin studies, respectively. Sitagliptin and vildagliptin studies ranged from 12 to 52 weeks duration. No data were published on mortality, diabetic complications, costs of treatment and health-related quality of life. Sitagliptin and vildagliptin therapy in comparison with placebo resulted in an HbA1c reduction of a...Continue Reading

References

Mar 1, 1992·Diabetes Care·R A DeFronzoE Ferrannini
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert
Jul 12, 2002·Statistics in Medicine·Julian P T Higgins, Simon G Thompson
May 22, 2003·JAMA : the Journal of the American Medical Association·Finlay A McAlisterDouglas G Altman
May 22, 2003·JAMA : the Journal of the American Medical Association·Nick FreemantleCarl Griffin
Sep 6, 2003·BMJ : British Medical Journal·Julian P T HigginsDouglas G Altman
Sep 17, 2003·Current Diabetes Reports·Bo Ahrén
Oct 16, 2004·The Journal of Clinical Endocrinology and Metabolism·Kathrin MaedlerMarc Y Donath
Jan 28, 2005·The Cochrane Database of Systematic Reviews·B Richter, G Neises
Apr 23, 2005·The Cochrane Database of Systematic Reviews·F A Van de LaarC Van Weel
Jul 22, 2005·The Cochrane Database of Systematic Reviews·A SaenzD Moher
Jan 27, 2006·The Cochrane Database of Systematic Reviews·S SalpeterE Salpeter
Mar 22, 2006·Expert Opinion on Investigational Drugs·Bo Ahrén
Apr 21, 2006·The Cochrane Database of Systematic Reviews·A SiebenhoferT R Pieber
Jul 11, 2006·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·R E PratleyD Holmes
Jul 21, 2006·The Cochrane Database of Systematic Reviews·D E ThomasG A Naughton
Jul 27, 2006·The Annals of Pharmacotherapy·Shannon Miller, Erin L St Onge
Sep 16, 2006·BMJ : British Medical Journal·Joseph LauIngram Olkin
Oct 21, 2006·The Cochrane Database of Systematic Reviews·B RichterS H Ebrahim
Nov 1, 2006·International Journal of Clinical Practice·A Barnett
Nov 15, 2006·Drugs·Sheridan Henness, Susan J Keam
Dec 13, 2006·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Brian D GreenClifford J Bailey
Jan 16, 2007·Diabetes Research and Clinical Practice·F Xavier Pi-SunyerSylvie Dejager
Feb 1, 2007·Diabetic Medicine : a Journal of the British Diabetic Association·J F Todd, S R Bloom
Feb 16, 2007·Diabetes, Obesity & Metabolism·Iskandar Idris, Richard Donnelly

❮ Previous
Next ❯

Citations

Nov 28, 2012·The Journal of Biological Chemistry·Jie TangZhulun Wang
Jan 22, 2010·International Journal of Clinical Practice·M Al-MaatouqK G M M Alberti
Jan 1, 2010·Drug, Healthcare and Patient Safety·Mary Elizabeth CoxJennifer B Green
Jan 1, 2010·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Karen BarnardJennifer B Green
Jan 1, 2009·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Jonathan K Reynolds
Feb 16, 2016·Fibrogenesis & Tissue Repair·Sen ShiKeizo Kanasaki
Apr 28, 2009·Atencion primaria·Eduard Diogène Fadini, Dolores Rodríguez Cumplido
Nov 23, 2016·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Islam Y ElgendyAnthony A Bavry
Jul 30, 2015·The Cochrane Database of Systematic Reviews·Bianca HemmingsenThomas P Almdal
Aug 7, 2008·The British Journal of General Practice : the Journal of the Royal College of General Practitioners·Neil Munro, Michael D Feher
Sep 9, 2011·The Cochrane Database of Systematic Reviews·Sinead BrophyRhys Williams
Sep 30, 2015·Diabetes/metabolism Research and Reviews·Wenjia YangLinong Ji
May 13, 2015·Clinical Pharmacology and Therapeutics·C A AlvarezD K McGuire
Jan 9, 2019·Der Internist·T LaurentiusL C Bollheimer
Feb 19, 2013·Diabetology & Metabolic Syndrome·Lilian Beatriz Aguayo Rojas, Marilia Brito Gomes
Jul 2, 2010·Diabetes, Obesity & Metabolism·A J Scheen
Dec 1, 2011·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Rupa Ahluwalia, Jiten Vora
Sep 3, 2013·Biological & Pharmaceutical Bulletin·Takuro KoboriShogo Tokuyama
Sep 2, 2014·European Journal of Clinical Pharmacology·George Grunberger
Mar 31, 2015·Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy·Toshiyuki NakaoUNKNOWN Japanese Society for Dialysis Therapy
Nov 27, 2009·Postgraduate Medicine·Anna I PalalauAnthony H Barnett
Jan 9, 2013·Nature Reviews. Cardiology·André J Scheen
May 21, 2015·QJM : Monthly Journal of the Association of Physicians·H-H ChenC-H Kao
Mar 16, 2017·British Journal of Clinical Pharmacology·Javier GorrichoAntonio López
Aug 2, 2019·International Journal of Environmental Research and Public Health·Konstantinos Makrilakis
Jun 13, 2015·European Heart Journal·Ele Ferrannini, Ralph A DeFronzo
Nov 7, 2019·Current Diabetes Reports·Christopher M MullaSamar Hafida

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.